HopeStage
Back to all studies
CompletedNCT01716975

EVP-6124 Added to Antipsychotics for Cognition in Schizophrenia

About this titleRead the official source — NCT01716975
Medication studyAges 18–50Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Listed locations
Phoenixville and 105 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2012
Recruitment status
Completed
Enrollment listed in the registry
767
Sponsor
FORUM Pharmaceuticals Inc
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Australia, United Kingdom, ...
Age range
From 18 Years to 50 Years
Official registry ID
NCT01716975
Official title
Show the full official title

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Phoenixville, United States · Little Rock, United States · Cerritos, United States

103 more locations
  • Chino, United States
  • Costa Mesa, United States
  • Garden Grove, United States
  • Glendale, United States
  • Norwalk, United States
  • Oakland, United States
  • Oakland Park, United States
  • Oceanside, United States
  • Riverside, United States
  • San Diego, United States
  • San Gabriel, United States
  • Santa Ana, United States
  • Sherman Oaks, United States
  • Washington D.C., United States
  • Bradenton, United States
  • Miami, United States
  • Miami Springs, United States
  • North Miami, United States
  • Orlando, United States
  • Marietta, United States
  • Smyrna, United States
  • Chicago, United States
  • Oak Brook, United States
  • Oak Park, United States
  • Wichita, United States
  • Lake Charles, United States
  • Shreveport, United States
  • Rockville, United States
  • Boston, United States
  • Saint Charles, United States
  • St Louis, United States
  • Lincoln, United States
  • Princeton, United States
  • Jamaica, United States
  • New York, United States
  • Rochester, United States
  • Charlotte, United States
  • Beachwood, United States
  • Oklahoma City, United States
  • Jenkintown, United States
  • Austin, United States
  • Dallas, United States
  • Salt Lake City, United States
  • Bellevue, United States
  • Richland, United States
  • Spokane, United States
  • Banfield, Argentina
  • Caba, Argentina
  • Mendoza, Argentina
  • Rosario, Argentina
  • Santiago del Estero, Argentina
  • Adelaide, Australia
  • Mount Claremont, Australia
  • Salvader, Brazil
  • Belo Horizonte, Brazil
  • Curitiba, Brazil
  • Medellín, Colombia
  • Barranquilla, Colombia
  • Pereira, Colombia
  • Bogota D.C., Colombia
  • Florence, Italy
  • Milan, Italy
  • Ban, Italy
  • Barl, Italy
  • Catania, Italy
  • Lucca, Italy
  • Pisa, Italy
  • Roma, Italy
  • Monterrey, Mexico
  • Mexico City, Mexico
  • San Luis Potosí City, Mexico
  • Bełchatów, Poland
  • Chełmno, Poland
  • Karakow, Poland
  • Kielce, Poland
  • Kotarbinskiego, Poland
  • Sosnowiec, Poland
  • Torun, Poland
  • Wroclaw, Poland
  • Campulung Muscel, Romania
  • Oradea, Romania
  • Cluj-Napoca, Romania
  • Palazu Mare, Romania
  • Iași, Romania
  • Târgu Mureş, Romania
  • Bucharest, Romania
  • Saint Petersburg, Russia
  • Smolensk, Russia
  • Moscow, Russia
  • Samara, Russia
  • Yaroslavl, Russia
  • Vil. Stepanivka, Ukraine
  • Dnipropetrovsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Poltava, Ukraine
  • Vinnytsia, Ukraine
  • Cambridge, United Kingdom
  • Newcastle upon Tyne, United Kingdom
  • Exeter, United Kingdom
  • London, United Kingdom
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is FORUM Pharmaceuticals Inc.

Did this study involve medication?

Yes. The study involved medication, including EVP-6124 and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies